Literature DB >> 7591050

The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants.

G H Chung1, K H Kim, R S Daum, R A Insel, G R Siber, S Sood, R K Gupta, C Marchant, M H Nahm.   

Abstract

Haemophilus influenzae type b (Hib) is a significant pathogen for young children, and three Hib vaccines (named PRP-OMPC, HbOC, and PRP-T) are currently available for young children. Extensive studies of anti-Hib polysaccharide (PS) antibodies (Abs) have shown that the V regions of Abs against the Hib PS comprise a VH gene in the VH3 gene family and a VL gene from various K kappa and V lambda subgroups. To study immunogenic properties of the three vaccines in young children, we determined the VL subgroups and avidities of anti-Hib-PS Abs induced by the three clinically available conjugate vaccines. Ab avidity was measured by determining the concentration of a Hib-PS oligomer that abrogates half of the binding of immunoglobulin G anti-Hib-PS Abs to microwells. The PRP-OMPC vaccine induced lower-avidity Abs than the prelicensure HbOC vaccine (P = 0.05). When we compared anti-Hib-PS Abs expressing V kappa Ia, V kappa II, and V lambda subgroups, a greater Ab response was induced by the prelicensure HbOC vaccine than other vaccines (P < 0.05). When anti-Hib-PS Abs with the V kappa III subgroup were compared, however, both PRP-T and prelicensure HbOC vaccines induced a comparable response, which in turn was greater than those induced by the PRP-OMPC or the postlicensure HbOC vaccine (P < 0.001). The VL repertoire of Abs induced with the prelicensure HbOC or PRP-T vaccine in young children is dominated (about 80%) by anti-Hib-PS Abs using subgroup V kappa II. However, anti-Hib-PS using V kappa II VL accounts for only about 40% of the total anti-Hib-PS Abs induced with the PRP-OMPC vaccine or the postlicensure HbOC. Our data suggest that immunogenic properties of Hib vaccines in young children vary depending on the vaccine preparations as well as the vaccine types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591050      PMCID: PMC173599          DOI: 10.1128/iai.63.11.4219-4223.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

Review 1.  The human antibody V region repertoire to the type B capsular polysaccharide of Haemophilus influenzae.

Authors:  M G Scott; H G Zachau; M H Nahm
Journal:  Int Rev Immunol       Date:  1992       Impact factor: 5.311

2.  Light chain isotypes selectively associate with heavy chain idiotypes in T-dependent and T-independent dextran-specific precursors.

Authors:  R E Ward; J F Kearney; H Köhler
Journal:  Nature       Date:  1981-08-13       Impact factor: 49.962

3.  Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group.

Authors:  D M Granoff; P G Shackelford; S J Holmes; A H Lucas
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

4.  Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group.

Authors:  D P Greenberg; C M Vadheim; S Partridge; S J Chang; C Y Chiu; J I Ward
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

5.  Isoelectric focusing of human antibody to the Haemophilus influenzae b capsular polysaccharide: restricted and identical spectrotypes in adults.

Authors:  R A Insel; A Kittelberger; P Anderson
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

Review 6.  Rational use of Haemophilus influenzae type b vaccine.

Authors:  Harry Campbell; Harden Carter
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide.

Authors:  P G Shackelford; D M Granoff; S J Nelson; M G Scott; D S Smith; M H Nahm
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

8.  Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type B polysaccharide. Demonstration of three types of V regions and their association with H and L chain isotypes.

Authors:  J J Tarrand; M G Scott; P A Takes; M H Nahm
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

9.  Restricted light chain subgroup expression on human rheumatoid factor paraproteins determined by monoclonal antibodies.

Authors:  R A Mageed; M R Walker; R Jefferis
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

10.  Functional capacities of clonal antibodies to Haemophilus influenzae type b polysaccharide.

Authors:  M H Nahm; K H Kim; P Anderson; S V Hetherington; M K Park
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  4 in total

1.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 3.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies.

Authors:  Mohammad M Sajadi; Maham Farshidpour; Eric P Brown; Xin Ouyang; Michael S Seaman; Marzena Pazgier; Margaret E Ackerman; Harriet Robinson; Georgia Tomaras; Matthew S Parsons; Manhattan Charurat; Anthony L DeVico; Robert R Redfield; George K Lewis
Journal:  J Infect Dis       Date:  2015-09-07       Impact factor: 5.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.